Furosemide vs Bumetanide: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Furosemide inhibits the NKCC2 sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, blocking reabsorption of sodium, potassium, and chloride. This forced mineral excretion creates a cascade: potassium and magnesium pour out in urine, calcium reabsorption drops, zinc clearance increases, and thiamine (B1) — a water-soluble vitamin — is washed out with the diuretic volume. CTD documents 105 gene interactions for furosemide, including effects on the renin-angiotensin-aldosterone system that compound electrolyte losses.
Furosemide has notoriously variable oral bioavailability — averaging 50% but ranging from 10% to 100% depending on edema, gut congestion, and food intake. Half-life is 1.5–2 hours with 98.4% protein binding.
- ✓ChEMBL documents 198 RCTs across 159,104 patients — the most-studied loop diuretic
- ✓First-line therapy for acute decompensated heart failure in every major guideline
- ✓Extremely low cost as a decades-old generic — critical for patients on lifelong therapy
- ✓Available in IV form for acute volume overload when oral absorption is compromised by gut edema
- ✗Wildly variable oral absorption (10–100%) makes depletion patterns unpredictable day to day
- ✗FAERS logs 239,189 adverse event reports — reflecting both widespread use and significant safety signals
- ✗Lower potency requires higher pill burden: 40 mg furosemide equals just 1 mg bumetanide
- ✗Thiamine depletion in heart failure patients creates a vicious cycle — B1 deficiency worsens cardiac function
Patients with stable heart failure who need cost-effective long-term diuresis, have reliable oral absorption, and can commit to comprehensive electrolyte and thiamine monitoring.
Bumetanide inhibits the same NKCC2 cotransporter as furosemide but with 40x higher binding affinity per milligram, producing equivalent diuresis at dramatically lower doses (1 mg bumetanide = 40 mg furosemide). CTD identifies 8 gene interactions for bumetanide — far fewer than furosemide's 105 — suggesting a more targeted molecular mechanism. Despite the higher potency, bumetanide causes identical mineral excretion patterns: potassium, magnesium, calcium, zinc, thiamine, and sodium all wash out through the same renal tubular mechanism.
Bumetanide achieves consistent 80% oral bioavailability — a major advantage over furosemide's unpredictable absorption. Half-life is 1–1.5 hours with 95% protein binding, and its absorption is less affected by gut edema.
- ✓Consistent 80% bioavailability means predictable diuresis and predictable mineral depletion patterns
- ✓40x potency reduces pill burden: 1 mg tablet versus 40 mg furosemide for equivalent effect
- ✓Only 8 CTD gene interactions versus furosemide's 105 — a dramatically narrower molecular footprint
- ✓Oral absorption maintained even in patients with significant gut edema from heart failure
- ✗Higher cost than generic furosemide — adds up for lifelong therapy plus supplementation
- ✗Fewer clinical trials: ChEMBL documents fewer RCTs than furosemide's 198
- ✗FAERS reports a 26.3% death-associated rate, partly reflecting use in sicker advanced heart failure patients
- ✗Same six-nutrient depletion burden as furosemide — higher potency doesn't mean fewer depletions
Patients with decompensated heart failure and gut edema limiting furosemide absorption, or those who need predictable diuretic response for reliable electrolyte management.
Feature Comparison
| Feature | Furosemide | Bumetanide |
|---|---|---|
| Drug Class | Loop diuretic (sulfonamide) | Loop diuretic (sulfonamide) |
| Nutrients Depleted | 6 — K, Mg, Ca, Zn, thiamine, Na | 6 — K, Mg, Ca, Zn, thiamine, Na |
| Potency Equivalence | 40 mg | 1 mg (40x more potent) |
| Oral Bioavailability | 10–100% (avg 50%) | 80% (consistent) |
| CTD Gene Interactions | 105 documented | 8 documented |
| FAERS Reports | 239,189 total | Fewer total (sicker population) |
| Half-Life | 1.5–2 hours | 1–1.5 hours |
| Primary Indications | Heart failure, edema, hypertension | Heart failure, edema (advanced/refractory) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both loop diuretics deplete the same six nutrients through identical NKCC2 cotransporter blockade — your electrolyte and thiamine supplementation protocol is the same for either drug. The practical difference is absorption reliability. Furosemide's wild 10–100% bioavailability range means some days you lose far more potassium and magnesium than others, making depletion management unpredictable. Bumetanide's consistent 80% absorption translates to predictable daily mineral losses that are easier to supplement against. CTD data reinforces the difference: furosemide's 105 gene interactions versus bumetanide's 8 suggest broader off-target metabolic effects. For patients with severe heart failure and gut edema — where furosemide absorption drops even further — bumetanide's reliable absorption makes it the superior choice. For stable outpatients on a budget, furosemide remains the global standard backed by 198 RCTs.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 105 gene interactions for furosemide including RAAS pathway genes; 8 gene interactions for bumetanide
- [2]ChEMBL bioactivity database: 198 RCTs for furosemide across 159,104 patients; bumetanide with fewer trials in advanced heart failure populations
- [3]FAERS (FDA Adverse Event Reporting System): 239,189 furosemide reports reflecting widespread global prescribing
- [4]PharmGKB pharmacogenomics database: NKCC2 (SLC12A1) transporter annotations for both drugs; SLCO1A2 variant effects on bumetanide clearance
- [5]PubMed PMID 17035649 — Sica DA. Loop diuretic therapy, thiamine balance, and heart failure. Congestive Heart Failure. 2007;13(4):244-247
Check your medications
Check Free →